Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 15Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 6Lymphoma 5Multiple Myeloma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Mantle-Cell 3Hodgkin Disease 3Breast Neoplasms 3Recurrence 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Hematologic Neoplasms 2Endometrial Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Ovarian Neoplasms 1Osteosarcoma 1

Interventions

X-Rays 4Phantoms, Imaging 4Specimen Handling 3Magnetic Resonance Spectroscopy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2ivosidenib 2Vemurafenib 2Triptorelin Pamoate 2Nuclear Medicine Department, Hospital 2LY3023414 2Drug Therapy 2surufatinib 1olaparib 1larotrectinib 1fludarabine 1erdafitinib 1ensartinib 1copanlisib 1bempegaldesleukin 1Zoledronic Acid 1Stem Cell Transplantation 1Sirolimus 1Proton Therapy 1Pharmacogenomic Variants 1Nivolumab 1Methionine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × copanlisib × Lymphoid × Clear all
NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Bayer

Phase 1/2 Terminated
31 enrolled 17 charts
CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡